| 43.32 2.32 (5.66%) | 04-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.8 | 1-year : | 61.67 |
| Resists | First : | 45.2 | Second : | 52.8 |
| Pivot price | 37.63  |
|||
| Supports | First : | 37.91 | Second : | 33.4 |
| MAs | MA(5) : | 38.53 |
MA(20) : | 37.93 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.3 |
Signal : | -0.9 |
| %K %D | K(14,3) : | 79 |
D(3) : | 59.2 |
| RSI | RSI(14): 62.7 |
|||
| 52-week | High : | 50.22 | Low : | 32.65 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CGON ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 41.25 - 41.42 | 41.42 - 41.58 |
| Low: | 36.12 - 36.29 | 36.29 - 36.45 |
| Close: | 40.7 - 40.99 | 40.99 - 41.27 |
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Wed, 21 Feb 2024
CG Oncology, Engene, and more line runway in bladder cancer - BioWorld Online
Tue, 30 Jan 2024
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase ... - Yahoo Finance Australia
Sun, 28 Jan 2024
StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M - Genetic Engineering & Biotechnology News
Thu, 25 Jan 2024
CG's IPO launches as NASDAQ's first biotech of 2024 - BioWorld Online
Thu, 25 Jan 2024
In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M - Fierce Biotech
Thu, 25 Jan 2024
Latham Watkins Advises CG Oncology on Initial Public Offering - Latham & Watkins LLP -
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -28 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 6.664e+007 (%) |
| Held by Institutions | 4.368e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 893 % |
| Return on Equity (ttm) | 200 % |
| Qtrly Rev. Growth | -31.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.543e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 3.05e+006 |
| Forward Dividend | 1.2e+006 |
| Dividend Yield | 7076570% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|